MTN-030/IPM 041

A Phase I trial of a vaginal ring containing the ARV drug dapivirine and the contraceptive hormone levonorgestrel that assessed the ring’s safety as well as absorption patterns of dapivirine and different dosages of levonorgestrel in vaginal tissue and in blood. MTN-030/IPM 041, which was conducted at two U.S. sites, found the ring was well-tolerated with no safety concerns. The study represents an important first step toward developing a product for women that could both protect against HIV and prevent unintended pregnancy. (See also MTN-044 and MTN-038.)

 

First clinical trial of new dapivirine ring with both anti-HIV drug and contraceptive

finds ring is well-tolerated with no safety concerns

24-October-2018

 

See Also

MTN-030/IPM 041 Protocol

 

MTN-030/IPM 041 Study Page

 

MTN begins first trial of new dapivirine ring with both anti-HIV drug and contraceptive

03-May-2017


Source URL: https://mtnstopshiv.org/news/mtn-030ipm-041